Summary
All provided claims are inconsistent with the supplied VYALEV (foscarbidopa/foslevodopa) FDA-approved prescribing information. The response incorrectly identifies VYALEV as leuprolide acetate and assigns an advanced prostate cancer indication/mechanism, whereas the label indicates advanced Parkinson’s disease motor fluctuations and describes carbidopa/levodopa-related mechanisms.
Category Scores
Accurate Statements
No accurate statements were supported by the supplied prescribing information.
The supplied label describes VYALEV as foscarbidopa/foslevodopa (prodrugs of carbidopa/levodopa) for advanced Parkinson’s disease motor fluctuations. None of the prostate cancer/leuprolide claims match the provided label excerpts.
Unsupported Statements
Vyalev is a brand name for leuprolide acetate.
The provided label indicates VYALEV contains foscarbidopa and foslevodopa (prodrugs of carbidopa and levodopa), not leuprolide acetate.
Leuprolide acetate is used to treat advanced prostate cancer.
The supplied label indication is for motor fluctuations in adults with advanced Parkinson’s disease, not advanced prostate cancer.
Leuprolide acetate is a hormonal (androgen deprivation) therapy.
The supplied label describes conversion to carbidopa and levodopa and does not describe an androgen deprivation mechanism.
Leuprolide acetate works by reducing testosterone levels in the body.
No testosterone-reduction mechanism is described in the supplied VYALEV label excerpts.
Reducing testosterone levels can slow the growth of prostate cancer that depends on androgens.
The supplied label does not support any prostate cancer mechanism or androgen/testosterone claim for VYALEV.
Vyalev is indicated for advanced prostate cancer.
The supplied label indicates VYALEV is for motor fluctuations in adults with advanced Parkinson’s disease.
Contradictions
High
AI Statement
Vyalev is a brand name for leuprolide acetate.
Label Reference
Drug identity/misc: Active ingredients listed as foscarbidopa and foslevodopa (prodrugs of carbidopa and levodopa).
High
AI Statement
Vyalev is indicated for advanced prostate cancer.
Label Reference
INDICATIONS AND USAGE: “VYALEV is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD).”
Important Omissions
The correct FDA-approved indication and identity for VYALEV (foscarbidopa/foslevodopa) for motor fluctuations in advanced Parkinson’s disease.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The claims misidentify the drug (leuprolide acetate vs foscarbidopa/foslevodopa) and misstate the indication/mechanism (prostate cancer androgen deprivation vs Parkinson’s disease motor fluctuations). These are material contradictions relative to the supplied FDA label and could lead to profoundly inappropriate use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major misidentification of VYALEV and assignment of an incorrect indication/mechanism (advanced prostate cancer/leuprolide).
Suggested Improvement
Replace all leuprolide/prostate cancer/androgen-testosterone claims with the label-supported information: VYALEV (foscarbidopa/foslevodopa; prodrugs of carbidopa/levodopa) is indicated for treatment of motor fluctuations in adults with advanced Parkinson’s disease, and omit unsupported prostate cancer hormonal mechanism statements.